trending Market Intelligence /marketintelligence/en/news-insights/trending/0B6bsS0_kefPOr-ocITbXQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lilly's pancreatic cancer drug fails to improve survival in late-stage trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Lilly's pancreatic cancer drug fails to improve survival in late-stage trial

Eli Lilly and Co.'s drug pegilodecakin in combination with chemotherapy Folfox did not meet the main goal of a late-stage study as the drug failed to improve overall survival in certain patients with a type of pancreatic cancer.

The Indianapolis-based pharmaceutical giant said the drug combination was being evaluated against the chemotherapy regimen alone in a phase 3 trial called Sequoia in patients with pancreatic cancer whose disease had progressed during or following an initial treatment with the chemotherapy gemcitabine.

Lilly said that patients receiving the drug combination experienced more adverse events — including low levels of platelets and neutropenia, a type of white blood cell, and anemia — compared to patients on Folfox alone.

The company said detailed efficacy and safety results will be submitted for presentation at a future medical meeting.

Lilly plans to turn its focus to pegilodecakin's clinical development in non-small cell lung cancer and other tumor types including renal cell carcinoma, a type of kidney cancer.

Lilly gained pegilodecakin in June 2018 following the $1.6 billion acquisition of ARMO BioSciences Inc.